NVO Stock Analysis: Buy, Sell, or Hold?
NVO - Novo-Nordisk A/S
$35.27
-0.77 (-2.15%)
▼
5d:
-4.22%
30d:
-5.83%
90d:
-32.7%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Distribution
NVO is up 3.0% this week, but smart money is buying puts. Top strike: $45 2026-04-17 with 20,502 OI. Put ratio: 65% View Scanner →
Strength: 3.0/10
Get Alerted When NVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NVO trading at deep discount. Market pricing in -8.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: NVO trading at deep discount. Market pricing in -8.7% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$57.44
Based on 3.5% avg growth
INTRINSIC VALUE TODAY
$35.67
1.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVO is currently trading at $35.27, which is considered oversold relative to its 30-day fair value range of $35.62 to $41.31. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.6) compared to its historical average (2.2). Remarkably, the market is currently pricing in an annual earnings decline of 8.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NVO is in a strong downtrend. The price is currently testing key support at $35.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $46.92 (+30.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVO is in a strong downtrend. The price is currently testing key support at $35.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $46.92 (+30.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$35.62 -
$41.31
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.2% below Wall St target ($46.92)
Fair Price Analysis
30-Day Fair Range
$35.62 -
$41.31
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$35.12
Resistance Level
$39.27
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.64
Wall Street Target
$46.92
(+30.2%)
Revenue Growth (YoY)
-7.6%
Earnings Growth (YoY)
-4.7%
Profit Margin
33.1%
Valuation Discount vs History
-8.7% cheaper
PE vs Historical
1.6 vs 2.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.7%
(market-implied from PE analysis)
1-Year Target
$32.90
(-9%)
2-Year Target
$30.04
(-17%)
3-Year Target
$27.43
(-24%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
$36.81
(+2%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 3.0%)
$538.78
(+1395%)
Base:
(SPY PE: 1.6, Growth: 3.0%)
$39.43
(+9%)
Bear:
(PE: 1.4, Growth: 3.0%)
$33.52
(-7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 10.35 | Current EPS (TTM): $3.53
Bull Case
$80.37
(+118%)
Analyst growth 100.0%, PE expands to 11.4
Base Case
$73.06
(+98%)
Market implied 100.0%, PE stable at 10.4
Bear Case
$24.84
(-33%)
Severe decline -20.0%, PE contracts to 8.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.6 to 2.2
Stabilization Target:
$48.37
(+34.2%)
PE Expansion Potential:
+34.2%
Share & Embed Analysis
Last updated: March 30, 2026 2:00 PM ET
Data refreshes hourly during market hours. Next update: 3:00 PM
Data refreshes hourly during market hours. Next update: 3:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 54 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 56 HOLD |
Advanced NVO Option Strategies
Professional options setups generated by AI based on today's NVO price and gamma walls.
